Prime Capital Investment Advisors LLC Purchases 3,873 Shares of IDEXX Laboratories, Inc. $IDXX

Prime Capital Investment Advisors LLC acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the third quarter, Holdings Channel reports. The institutional investor acquired 3,873 shares of the company’s stock, valued at approximately $2,022,000.

Several other hedge funds have also recently added to or reduced their stakes in IDXX. Bank of New York Mellon Corp bought a new position in IDEXX Laboratories during the second quarter worth about $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of IDEXX Laboratories by 4.6% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock valued at $479,844,000 after acquiring an additional 39,700 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of IDEXX Laboratories by 52.4% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock valued at $471,335,000 after acquiring an additional 288,471 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of IDEXX Laboratories by 4.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock valued at $322,145,000 after acquiring an additional 23,582 shares during the period. Finally, Alyeska Investment Group L.P. raised its position in shares of IDEXX Laboratories by 97.3% in the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock valued at $211,146,000 after acquiring an additional 197,808 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.8%

Shares of IDEXX Laboratories stock opened at $553.48 on Thursday. IDEXX Laboratories, Inc. has a 1 year low of $500.61 and a 1 year high of $769.98. The business has a 50-day moving average of $532.51 and a two-hundred day moving average of $551.60. The company has a market capitalization of $43.60 billion, a P/E ratio of 38.92, a price-to-earnings-growth ratio of 2.98 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The company had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same quarter last year, the firm posted $3.50 earnings per share. IDEXX Laboratories’s revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

Insider Transactions at IDEXX Laboratories

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.79% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the topic of several recent analyst reports. Barclays reduced their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. JPMorgan Chase & Co. lowered their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research note on Friday, October 16th. The Goldman Sachs Group started coverage on shares of IDEXX Laboratories in a research report on Friday, October 16th. They set a “buy” rating and a $740.00 price target on the stock. Finally, Citigroup boosted their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Seven research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $744.09.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.